Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: An Eastern Cooperative Oncology Group trial (E3393)

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 24, Issue 1, 2001, Pages 64-66

  Murphy, Barbara A ^a   Leong, Traci ^b   Burkey, Brian ^a   Langer, Corey ^c   Forastiere, Arlene ^d  

^a VANDERBILT UNIVERSITY   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Head and neck cancer; Metastatic disease; Squamous carcinoma; Topotecan; Treatment

Indexed keywords

TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFICACY; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; MALE; METASTASIS; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; TOPOTECAN;

EID: 0035113966     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200102000-00011     Document Type: Article

References (10)

1. Systemic therapy of head and neck cancer: Most effective agents, areas of promise
2. New drug therapy for squamous carcinoma of the head and neck
3. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials
4. Topoisomerase inhibitors, a review of their therapeutic potential in cancer
5. Recent clinical advances with camptothecin analogues
6. Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor
7. Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent
8. Nonparametric estimation from incomplete observations
9. A phase II study of topotecan in patients with recurrent head and neck cancer. Identification of an active new agent
10. Evaluation of topotecan in patients with recurrent or metastatic squamous cell carcinoma of the head and neck